Management ChangeApr 23, 2026, 04:32 PM
Corvus Pharma Appoints Andrew C. Chan, M.D., Ph.D. to Board
AI Summary
Corvus Pharmaceuticals, Inc. announced the appointment of Andrew C. Chan, M.D., Ph.D., to its Board of Directors, effective April 23, 2026. Dr. Chan will serve as a Class II director with a term expiring at the 2027 annual meeting and was also appointed to the Nominating and Corporate Governance Committee. His compensation includes a $35,000 annual Board retainer, an initial stock option grant for 30,000 shares, and an additional $4,000 annually for his committee service.
Key Highlights
- Andrew C. Chan, M.D., Ph.D., appointed to Board of Directors.
- Effective April 23, 2026, as a Class II director.
- Receives $35,000 annual retainer for Board service.
- Granted initial stock option for 30,000 shares.
- Additional $4,000 annual compensation for Nominating Committee service.
Price Impact
More from CRVS